EGFR (D770_N771insNPG)

EGFR · Variant type: indel · HGVS: p.D770_N771insNPG

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Osimertinib	100.0%	0.0%	97.24
2	Afatinib	100.0%	0.0%	98.50
3	Pralsetinib	99.7%	0.3%	93.43
4	Mobocertinib	99.3%	0.7%	97.22
5	Canertinib	99.1%	0.9%	96.49
6	Dacomitinib	99.0%	1.0%	97.99
7	Lazertinib	97.7%	2.3%	97.47
8	Bosutinib	97.5%	2.5%	87.22
9	Gefitinib	97.0%	3.0%	99.25
10	Fostamatinib	96.0%	4.0%	96.74
11	Neratinib	94.6%	5.4%	93.18
12	Alpelisib	92.7%	7.3%	97.22
13	Dasatinib	89.9%	10.1%	87.97
14	Brigatinib	89.3%	10.7%	82.96
15	Vandetanib	85.3%	14.7%	95.74
16	Pacritinib	79.4%	20.6%	88.64
17	Erlotinib	73.5%	26.5%	99.75
18	Ibrutinib	62.6%	37.4%	94.74
19	Pemigatinib	51.8%	48.2%	98.23
20	Fedratinib	43.3%	56.7%	96.21
21	Nintedanib	32.2%	67.8%	90.23
22	Pexidartinib	31.8%	68.2%	99.49
23	Lorlatinib	31.7%	68.3%	97.24
24	Zanubrutinib	30.8%	69.2%	98.24
25	Gilteritinib	29.5%	70.5%	88.97

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Osimertinib	100.0%	99.1%	+0.9%
Afatinib	100.0%	100.0%	+0.0%
Pralsetinib	99.7%	99.1%	+0.6%
Mobocertinib	99.3%	100.0%	-0.7%
Canertinib	99.1%	98.4%	+0.6%
Dacomitinib	99.0%	99.8%	-0.8%
Lazertinib	97.7%	100.0%	-2.3%
Bosutinib	97.5%	99.3%	-1.8%
Gefitinib	97.0%	99.9%	-2.9%
Fostamatinib	96.0%	97.8%	-1.7%
Neratinib	94.6%	100.0%	-5.4%
Alpelisib	92.7%	—	—
Dasatinib	89.9%	97.9%	-8.0%
Brigatinib	89.3%	98.5%	-9.2%
Vandetanib	85.3%	99.3%	-14.0%
Pacritinib	79.4%	—	—
Erlotinib	73.5%	99.4%	-26.0%
Ibrutinib	62.6%	99.3%	-36.8%
Pemigatinib	51.8%	—	—
Fedratinib	43.3%	—	—
Nintedanib	32.2%	—	—
Pexidartinib	31.8%	—	—
Lorlatinib	31.7%	—	—
Zanubrutinib	30.8%	88.2%	-57.4%
Gilteritinib	29.5%	91.0%	-61.5%

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 18.2ms